MultiCell Technologies Inc MCET
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $5,000.95
- Volume/Avg
- 8.5 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize and differentiate stem cells from human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company’s medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 2
- Website
- http://www.multicelltech.com
Valuation
|
Metric
|
MCET
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MCET
|
|---|---|
Quick Ratio | 0.18 |
Current Ratio | 0.19 |
Interest Coverage | −102.18 |
Quick Ratio
MCET
Profitability
|
Metric
|
MCET
|
|---|---|
Return on Assets (Normalized) | −212.38% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
MCET
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yckqblhkz | Kfr | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ywlrzdkq | Jgywdw | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pgkhphjfx | Ntfgll | $98.1 Bil | |
MRNA
| Moderna Inc | Zwkfgbykr | Zxnn | $39.1 Bil | |
ARGX
| argenx SE ADR | Shdwbyp | Whbls | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Jsndmsszh | Vqqj | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Stddwdtyl | Jvszcx | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gbcfdsq | Lmsgz | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Frjrnnmygn | Fbkvlpk | $12.5 Bil | |
INCY
| Incyte Corp | Qgjmbrz | Vjddgp | $11.9 Bil |